Results 221 to 230 of about 53,113 (297)

Fatal Tumor Lysis Syndrome Induced by Pembrolizumab in Advanced Renal Pelvis Cancer

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Tumor lysis syndrome (TLS) arises from the rapid breakdown of tumor cells during oncological treatment. Although TLS is rarely observed in solid tumors, few studies have documented instances of TLS associated with pembrolizumab. This report presents a case involving pembrolizumab‐induced TLS.
Takashi Asakura, Toshiaki Shinojima, Shinnosuke Hiruta, Hirotaka Asakura   +3 more
wiley   +1 more source

Effectiveness and Safety of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter, Retrospective Real-World Study in China. [PDF]

Clin Med Insights Oncol
Shao M, Tan B, Fan C, Fu Y, Chen H, Liu P, Zhang H.   +6 more
europepmc   +1 more source

Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Aim The gut microbiome modulates immune responses, and butyrate‐producing bacteria have been linked to improved immune checkpoint inhibitor (ICI) efficacy. Conversely, proton pump inhibitors (PPIs) may negatively impact ICI outcomes by altering gut microbiota.
Kazuhiro Nouso, Akiko Wakuta, Shohei Shiota, Rio Fujita, Kazuya Kariyama, Atsushi Hiraoka, Masanori Atsukawa, Joji Tani, Toshifumi Tada, Shinichiro Nakamura, Kazuto Tajiri, Masaki Kaibori, Masashi Hirooka, Ei Itobayashi, Satoru Kakizaki, Atsushi Naganuma, Toru Ishikawa, Michitaka Imai, Tomoko Aoki, Hironori Tanaka, Takeshi Hatanaka, Kunihiko Tsuji, Kazuhito Kawata, Koichi Takaguchi, Akemi Tsutsui, Chikara Ogawa, Hironori Ochi, Yutaka Yata, Hidekatsu Kuroda, Tomomitsu Matono, Satoshi Yasuda, Hidenori Toyoda, Hiroko Iijima, Masatoshi Kudo, Takashi Kumada   +34 more
wiley   +1 more source

Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer. [PDF]

Sci Rep
Chen HL, Chueh CH, Huang WM, Chan SH, Cheng HH, Chiang SC, Wu CE, Wen YW, Tsai YW.   +8 more
europepmc   +1 more source

Combining immunotherapy with radiation therapy in thoracic oncology [PDF]

, 2018
Badiyan, Shahed N, Chilukuri, Srinivas, Chuong, Michael D, Glass, Erica, Mohindra, Pranshu, Onyeuku, Nasarachi E, Remick, Jill, Rice, Stephanie R, Roach, Michael C, Simone, Charles B, II   +9 more
core   +1 more source

Breast Cancer: Molecular Pathogenesis, Targeted Therapy, Screening, and Prevention

MedComm, Volume 7, Issue 1, January 2026.
The review manuscript examines the molecular pathogenesis, screening, prevention advances, and evolving targeted therapies in breast cancer. It highlights the integration of AI and multiomics for precision prevention and personalized treatment, pointing toward future directions in equitable cancer care.
Huijun Lei, Jinzhen Fu, Wei Gu, Hongjin Qiao, Huixue Guo, Zijian Chen, San Ming Wang, Tianhui Chen   +7 more
wiley   +1 more source

Case Report: Unexpected non-pathogenic autoantibodies without clinical involvement following PD-L1 blockade. [PDF]

Front Immunol
Zhang L, Jin Z, Wang S.
europepmc   +1 more source

Letter regarding “Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study”

Takeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, Satoru Kakizaki   +3 more
openalex   +1 more source

Melanoma: Pathogenesis and Targeted Therapy

MedComm, Volume 7, Issue 1, January 2026.
The treatment landscape for advanced melanoma has evolved significantly. BRAF–MEK inhibitor combinations are standard for BRAF‐mutant melanoma, whereas targeting NRAS mutations is more challenging, with MEK inhibitors like tunlametinib emerging as an option.
Yang Fu, Jie Liu, Zeming Mo, Bin Wang, Yaotiao Deng, Yu Jiang   +5 more
wiley   +1 more source

A bibliometric analysis of atezolizumab in hepatocellular carcinoma. [PDF]

Discov Oncol
Xu Y, Zhang H, Yu H.
europepmc   +1 more source